VeriStrat: Data

An analysis of 441 patients from the Phase III BR.21 trial of Tarceva erlotinib to treat NSCLC showed that VeriStrat successfully identified patients who were likely to have a significant survival benefit with the small molecule EGFR inhibitor. Specifically, Tarceva-treated patients that were classified as "VeriStrat Good" had a significant improvement in median survival vs. placebo (10.5 vs. 6.6 months, p=0.002), whereas Tarceva-treated patients that were classified as "VeriStrat Poor" had no significant improvement in survival vs. placebo (4 vs. 3.1 months, p=0.11). Additionally, "VeriStrat Good" patients had a significantly higher tumor response rate vs. "VeriStrat Poor" patients (11.5% vs. 1%, p=0.002). Data were presented at the European Lung Cancer meeting in Geneva. ...